198 related articles for article (PubMed ID: 17635930)
1. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.
Koh Y; Matsumi S; Das D; Amano M; Davis DA; Li J; Leschenko S; Baldridge A; Shioda T; Yarchoan R; Ghosh AK; Mitsuya H
J Biol Chem; 2007 Sep; 282(39):28709-28720. PubMed ID: 17635930
[TBL] [Abstract][Full Text] [Related]
2. Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1.
Koh Y; Aoki M; Danish ML; Aoki-Ogata H; Amano M; Das D; Shafer RW; Ghosh AK; Mitsuya H
J Virol; 2011 Oct; 85(19):10079-89. PubMed ID: 21813613
[TBL] [Abstract][Full Text] [Related]
3. The higher barrier of darunavir and tipranavir resistance for HIV-1 protease.
Wang Y; Liu Z; Brunzelle JS; Kovari IA; Dewdney TG; Reiter SJ; Kovari LC
Biochem Biophys Res Commun; 2011 Sep; 412(4):737-42. PubMed ID: 21871444
[TBL] [Abstract][Full Text] [Related]
4. Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.
Hayashi H; Takamune N; Nirasawa T; Aoki M; Morishita Y; Das D; Koh Y; Ghosh AK; Misumi S; Mitsuya H
Proc Natl Acad Sci U S A; 2014 Aug; 111(33):12234-9. PubMed ID: 25092296
[TBL] [Abstract][Full Text] [Related]
5. Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.
Aoki M; Danish ML; Aoki-Ogata H; Amano M; Ide K; Das D; Koh Y; Mitsuya H
J Virol; 2012 Dec; 86(24):13384-96. PubMed ID: 23015723
[TBL] [Abstract][Full Text] [Related]
6. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
Norelli S; El Daker S; D'Ostilio D; Mele F; Mancini F; Taglia F; Ruggieri A; Ciccozzi M; Cauda R; Ciervo A; Barreca ML; Pistello M; Bendinelli M; Savarino A
Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
[TBL] [Abstract][Full Text] [Related]
7. Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.
Windsor IW; Raines RT
Sci Rep; 2015 Aug; 5():11286. PubMed ID: 26261098
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease.
Davis DA; Brown CA; Singer KE; Wang V; Kaufman J; Stahl SJ; Wingfield P; Maeda K; Harada S; Yoshimura K; Kosalaraksa P; Mitsuya H; Yarchoan R
Antiviral Res; 2006 Nov; 72(2):89-99. PubMed ID: 16687179
[TBL] [Abstract][Full Text] [Related]
9. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors.
Talbot A; Grant P; Taylor J; Baril JG; Liu TF; Charest H; Brenner B; Roger M; Shafer R; Cantin R; Zolopa A
Antimicrob Agents Chemother; 2010 Jun; 54(6):2473-9. PubMed ID: 20368406
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.
Brower ET; Bacha UM; Kawasaki Y; Freire E
Chem Biol Drug Des; 2008 Apr; 71(4):298-305. PubMed ID: 18312292
[TBL] [Abstract][Full Text] [Related]
11. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Arribas JR
Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
[TBL] [Abstract][Full Text] [Related]
12. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
13. Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors.
Peatey CL; Andrews KT; Eickel N; MacDonald T; Butterworth AS; Trenholme KR; Gardiner DL; McCarthy JS; Skinner-Adams TS
Antimicrob Agents Chemother; 2010 Mar; 54(3):1334-7. PubMed ID: 20028821
[TBL] [Abstract][Full Text] [Related]
14. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
Muzammil S; Armstrong AA; Kang LW; Jakalian A; Bonneau PR; Schmelmer V; Amzel LM; Freire E
J Virol; 2007 May; 81(10):5144-54. PubMed ID: 17360759
[TBL] [Abstract][Full Text] [Related]
15. Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.
Janakiraman MN; Watenpaugh KD; Tomich PK; Chong KT; Turner SR; Tommasi RA; Thaisrivongs S; Strohbach JW
Bioorg Med Chem Lett; 1998 May; 8(10):1237-42. PubMed ID: 9871742
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Protease Dimerization Dynamics Reveals a Transient Druggable Binding Pocket at the Interface.
Pietrucci F; Vargiu AV; Kranjc A
Sci Rep; 2015 Dec; 5():18555. PubMed ID: 26692118
[TBL] [Abstract][Full Text] [Related]
17. Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing.
Davis DA; Soule EE; Davidoff KS; Daniels SI; Naiman NE; Yarchoan R
Antimicrob Agents Chemother; 2012 Jul; 56(7):3620-8. PubMed ID: 22508308
[TBL] [Abstract][Full Text] [Related]
18. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
[TBL] [Abstract][Full Text] [Related]
19. Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease.
Kovalevsky AY; Louis JM; Aniana A; Ghosh AK; Weber IT
J Mol Biol; 2008 Dec; 384(1):178-92. PubMed ID: 18834890
[TBL] [Abstract][Full Text] [Related]
20. Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan.
Hsieh SM; Chang SY; Hung CC; Sheng WH; Chen MY; Chang SC
Int J STD AIDS; 2011 Nov; 22(11):617-20. PubMed ID: 22096044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
